Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Will the Gastric Cancer Therapy Market Evolve in Terms of Growth and Size by 2029?
The market for gastric cancer treatments has been witnessing considerable expansion in the past few years. Its size is projected to surge from $4.12 billion in 2024 to $4.50 billion in 2025, charting a compound annual growth rate (CAGR) of 9.3%. Factors that fueled this robust growth during the historical period include the escalating incident rates of h. pylori infection, augmented intake of tobacco and alcohol, an increasing elderly populace, a scarcity of early detection tools, and the wide-scale implementation of chemotherapy.
Strong expansion is anticipated in the gastric cancer therapy market size over the coming years, forecasted to reach $6.39 billion by 2029 with a CAGR of 9.1%. This predicted growth through the forecast period is largely due to the upsurge in biomarker-based treatments, a growing prevalence of combination treatment strategies, significant investment in oncology R&D, improvements in healthcare infrastructure within developing economies, and the uptake of liquid biopsies for monitoring purposes. The forecast period is also likely to see major trends such as the advancement of personalized medicines, emphasis on targeted drug delivery systems, more clinical trials for innovative antibodies, the incorporation of AI into diagnostic imaging, and the development of combination therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp
What factors are expected to fuel Gastric Cancer Therapy market growth in the coming years?
The increasing frequency of helicobacter pylori infection is anticipated to fuel the expansion of the gastric cancer therapy market in the future. This bacterial infection primarily impacts the stomach’s lining and is a significant contributor to chronic gastritis and gastric cancer. The escalating frequency of helicobacter pylori infection is largely due to inadequate sanitation, as substandard hygiene practices and tainted food or water sources enable the transmission of the bacteria orally or fecally. Gastric cancer therapy serves to lower the risk of gastric cancer that comes from helicobacter pylori infection by addressing the infection, reducing related gastric inflammation and cellular damage, and hindering the advancement of chronic gastritis and atrophic modifications that can lead to the malignant transformation of the gastric mucosa. For example, in November 2024, a report published by the Government of Canada, a government administration based in Canada, stated that the recurrence rate of H. pylori infection might be as high as 19% as of January 2023, although it is variable and depends on age and geographical region. Consequently, the escalating frequency of helicobacter pylori infection is boosting the growth of the gastric cancer therapy market.
What Are The Key Findings From The Segmentation Analysis Of The Gastric Cancer Therapy Market?
The gastric cancer therapy market covered in this report is segmented –
1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents
3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous
4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage
5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings
Subsegments:
1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy
2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy
5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy
Which Trends Are Expected To Shape The Future Of The Gastric Cancer Therapy Market?
The key players in the gastric cancer therapy market are concentrating their efforts on the creation of groundbreaking treatment methods, such as combination therapy, to boost the effectiveness of treatment and patient outcomes. Combination therapy implies the use of two or more treatments, such as chemotherapy, targeted therapy, or immunotherapy, in conjunction to increase overall effectiveness. For example, BeOne Medicines Ltd., a pharmaceutical company formerly known as BeiGene based in China, attained approval from the U.S. Food and Drug Administration (FDA) in December 2024 for Tevimbra (tislelizumab-jsgr) to be used in combination with platinum- and fluoropyrimidine-based chemotherapy as the initial treatment for adults suffering from inoperable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma where the tumors reveal PD-L1 (=1) expression. This endorsement came about due to the results garnered from the Phase 3 RATIONALE-305 trial which showed that combining the therapies remarkably enhanced the median overall survival to 15.0 months as opposed to 12.9 months when using just chemotherapy, depicting a 20% decrease in the chance of mortality. This achievement emphasized an emerging pattern among dominant pharmaceutical firms of investing in pioneering, multifaceted treatment techniques that merge immunotherapy with traditional chemotherapy treatments to improve clinical results, postpone disease advancement, and enhance survival rates among patients diagnosed with advanced gastric cancer.
What Are The Most Active Companies In The Gastric Cancer Therapy Market Today?
Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, LintonPharm Co. Ltd.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report
Which Regional Markets Are Attracting The Most Investment In Gastric Cancer Therapy?
North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25767&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model